Evaluation of Ondansetron-induced QT interval prolongation in the prophylaxis of postoperative emesis

Journal of Natural Science, Biology and Medicine

Volumn 2, Issue 1, 2011, Pages 119-124

  Gupta, Sampa Dutta ^a   Pal, Ranabir ^b   Sarkar, Aniruddha ^a   Mukherjee, Sudakshina ^a   Mitra, Koel ^a   Roy, Suddhadeb ^a   Sarbapalli, Debabrata ^c   Kundu, Kanak Kanti ^a   Zaman, Forhad Akhtar ^b   Kar, Sumit ^b  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b SIKKIM MANIPAL INSTITUTE OF MEDICAL SCIENCES   (India)

^c BURDWAN MEDICAL COLLEGE   (India)

Author keywords

Ondansetron; Postoperative nausea vomiting; QT interval corrected for heart rate

Indexed keywords

EID: 84876515395     PISSN: 09769668     EISSN: 22297707     Source Type: Journal    
DOI: 10.4103/0976-9668.82306     Document Type: Article

References (16)

1. Goodin S, Cunningham R. 5-HT3-receptor antagonists for the treatment of nausea and vomiting: A reappraisal of their side-eff ect profi le. Oncologist 2002;7:424-36.
2. Tramèr MR, Reynolds DJ, Moore RA, McQuay HJ. Effi cacy, doseresponse, and safety of Ondansetron in prevention of postoperative nausea and vomiting: A qualitative systematic review of randomized placebo-controlled trials. Anesthesiology 1997;87:1277-89.
3. Gan TJ, Meyer T, Apfel CC, Chung F, Davis PJ, Eubanks S, et al. Consensus Guidelines for Managing Postoperative Nausea and Vomiting. Anesth Analg 2003;97:62-71.
4. Charbit B, Albaladejo P, Funck-Brentano C, Legrand M, Samain E, Marty J. Prolongation of QTc interval aft er postoperative nausea and vomiting treatment by droperidol or Ondansetron. Anesthesiology 2005;102:1094-100.
5. Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: Implications for drug approval and labeling. Drug Saf 2001;24:323-51.
6. Roden DM. A Practical Approach to Torsade de Pointes. Clin Cardiol 20;1997:285-90.
7. Helmers JH, Briggs L, Abrahamsson J, Soni J, Moodley J, Forrler M, et al. A. single i.v. dose of Ondansetron 8 mg prior to induction of anaesthesia reduces postoperative nausea and vomiting in gynaecological participants. Can J Anesth 1993;40:1155-61.
8. Chan MT, Choi KC, Gin T, Chui PT, Short TG, Yuen PM, et al. The additive interactions between Ondansetron and droperidol for preventing postoperative nausea and vomiting. Anesth Analg 2006;103:1155-62.
9. Bazett HC. An analysis of the time - relations of electro-cardiograms. Heart 1920;7:353-70.
10. Moss AJ, Zareba W, Hall WJ, Schwartz PJ, Crampton RS, Benhorin J, et al. Eff ectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 2000;101:616-23.
11. Vincent GM, Timothy K, Zhang L. Congenital long QT syndrome. Cardiac Electrophysiol Rev 2002;6:57-60.
12. Viskin S. Cardiac pacing in the long QT syndrome: Review of available data and practical recommendations. J Cardiovasc Electrophysiol 2000;11:593-600.
13. Singh BN. When is QT prolongation antiarrhythmic and when is it proarrhythmic? Am J Cardiol 1989;63:867-9.
14. Sun R, Klein KW, White PF. The eff ect of timing of Ondansetron administration in outparticipants undergoing otolaryngologic surgery. Anesth Analg 1997;84;331-6.
15. Tramèr MR, Reynolds DJ, Moore RA, McQuay HJ. Effi cacy, doseresponse, and safety of Ondansetron in prevention of postoperative nausea and vomiting: A qualitative systematic review of randomized placebo-controlled trials. Anesthesiology 1997;87:1277-89.
16. Tramèr MR, Philips C, Reynolds DJ, McQuay HJ, Moore RA. Costeff ectiveness of ondansetron for postoperative nausea and vomiting. Anaesthesia 1999;54:226-35.